Short Interest in Longeveron Inc. (NASDAQ:LGVN) Grows By 224.2%

Longeveron Inc. (NASDAQ:LGVN) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 91,100 shares, an increase of 224.2% from the March 31st total of 28,100 shares. Based on an average daily volume of 2,010,000 shares, the short-interest ratio is currently 0.0 days. Approximately 9.3% of the company’s stock are short sold.

Longeveron Stock Performance

Longeveron stock opened at $1.67 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.50 and a quick ratio of 1.50. Longeveron has a 12 month low of $1.60 and a 12 month high of $44.00. The company has a fifty day moving average price of $3.76 and a two-hundred day moving average price of $11.14. The company has a market cap of $4.19 million, a PE ratio of -0.16 and a beta of 0.21.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($2.50) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.40). Longeveron had a negative net margin of 3,020.17% and a negative return on equity of 209.14%. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.21 million. Research analysts expect that Longeveron will post -8.5 earnings per share for the current year.

Insider Activity

In related news, Director Rock Soffer acquired 31,915 shares of Longeveron stock in a transaction on Thursday, April 11th. The shares were purchased at an average cost of $2.35 per share, for a total transaction of $75,000.25. Following the purchase, the director now directly owns 208,534 shares of the company’s stock, valued at approximately $490,054.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Joshua Hare bought 106,383 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The stock was bought at an average price of $2.35 per share, for a total transaction of $250,000.05. Following the transaction, the insider now owns 590,727 shares in the company, valued at $1,388,208.45. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rock Soffer purchased 31,915 shares of the stock in a transaction dated Thursday, April 11th. The stock was purchased at an average price of $2.35 per share, with a total value of $75,000.25. Following the completion of the acquisition, the director now directly owns 208,534 shares in the company, valued at approximately $490,054.90. The disclosure for this purchase can be found here. In the last three months, insiders acquired 148,936 shares of company stock worth $350,000. 24.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. Armistice Capital LLC purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,836,000 shares of the company’s stock, valued at approximately $2,497,000. Armistice Capital LLC owned about 7.31% of Longeveron at the end of the most recent quarter. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.